c19early.org
Gabapentin for COVID-19
1 study with 129 patients
Serious outcome risk
Gabapentin
Control
COVID-19 Gabapentin studies · October 2026
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−11%
Hospitalization (1)−11%
RCTs (1)−11%
Late (1)−11%
00.511.5+
← Gabapentin
reduces risk
Increased
risk →
Aug 31
2025
Pan et al., Biomedicines, doi:10.3390/biomedicines13092133 CX3CR1–TLR4 Axis as a Shared Neuroimmune Target in COVID-19 and Epilepsy: Integrative Transcriptomics and Gabapentin Repositioning
In silico study showing that gabapentin may be beneficial for COVID-19 treatment through shared neuroinflammatory pathways with epilepsy. Authors performed integrative transcriptomic analysis of COVID-19 peripheral blood mononuclear cells..
Jul 31
2022
Soltani et al., The Clinical Respiratory Journal, doi:10.1111/crj.13529 The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID‐19‐ related cough: A randomized, controlled clinical trial
11% longer hospitalization (p=0.23) and 97% worse recovery (p<0.0001). RCT 180 hospitalized COVID-19 patients showing improved cough symptoms and shorter hospitalization with montelukast/gabapentin compared to gabapentin. For gabapentin vs. dextromethorphan there was no significant difference in hospitalizat..